You are here

Develop and Commercialize the Bayesian Dose-Response Modeling System and Services

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 9R42ES032642-02
Agency Tracking Number: R42ES032642
Amount: $2,046,603.00
Phase: Phase II
Program: STTR
Solicitation Topic Code: NIEHS
Solicitation Number: PA19-270
Solicitation Year: 2019
Award Year: 2020
Award Start Date (Proposal Award Date): 2020-07-24
Award End Date (Contract End Date): 2022-06-30
Small Business Information
Bloomington, IN 47401-8017
United States
DUNS: 080461222
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 (812) 856-2725
Business Contact
Phone: (812) 856-2725
Research Institution
United States

 Nonprofit College or University

Chemical risk assessment is widely applied in industries and regulatory agencies as an important tool to
evaluate chemical toxicity in support of chemical registration, safety evaluation, and exposure limitation
development. One of the most notable improvements in dose-response assessment - a required quantitative
step in risk assessment - is the development of benchmark dose (BMD) methodology to better utilize
toxicological information to facilitate toxicity evaluation of chemicals. Although the BMD method has been
advocated by the US Environmental Protection Agency (EPA) and European Food Safety Authority (EFSA) for
its scientific advantages (such as less dependency on the design of experiments and more plausible
interpretation on uncertainty) for years, the employment of the method in practical risk assessment has been
significantly hindered by a few important limitations, one of which is the lack of a reliable modeling system to
support consistent practice of BMD modeling across different sectors. Therefore, based on the Bayesian
benchmark dose modeling system (BBMD) prototype successfully built in Phase I of the STTR project, the
objective of Phase II is to further the development of the BBMD system to meet more diverse needs in dose-
response assessment and to enlarge the user base of the system as an essential component for
commercialization. The rational is that, given relatively limited practical implementation of BMD modeling for
dose-response assessment in industry and some government agencies, demonstrating and improving the
utility of the BMD method rather than sophisticating the methodology are more appropriate at the current stage
to enhance the acceptance of BMD method and then create business opportunities for the company. To
accomplish this objective, three specific aims will be pursued: (1) develop a Bayesian BMD modeling approach
with software for typical epidemiological dose-response data; (2) develop a Bayesian BMD modeling approach
with software for high-throughput dose-response data; (3) upgrade the BBMD to a data computation and
management system to perform, store, and distribute BMD analyses approved by a panel of experts. The
success of the project will fill multiple gaps that hamper the large-scale adoption of BMD methodology in
industry and government. Meanwhile, Dream Tech will increase the influence of the BBMD system and build
up user base through an array of channels to commercialize the dose-response modeling platform and
services in support of chemical risk assessment.PROJECT NARRATIVE
The Phase II of the STTR Project is to further the development of the Bayesian benchmark dose modeling
system (BBMD) started in Phase I to meet more diverse needs in dose-response assessment and to fill
multiple gaps that hamper the large-scale adoption of BMD methodology in industry and government, which
will be a major step forward in chemical risk assessment and safety evaluation for protecting public health from
chemical exposure.

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government